Both Novelion Therapeutics Inc. (NASDAQ:NVLN) and Coherus BioSciences Inc. (NASDAQ:CHRS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novelion Therapeutics Inc.	130.43M	0.21	108.33M	-6.05	0.00
Coherus BioSciences Inc.	N/A	0.00	209.34M	-3.13	0.00

Table 1 demonstrates Novelion Therapeutics Inc. and Coherus BioSciences Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Novelion Therapeutics Inc. and Coherus BioSciences Inc.

	Net Margins	Return on Equity	Return on Assets
Novelion Therapeutics Inc.	-83.06%	404.3%	-32.6%
Coherus BioSciences Inc.	0.00%	-742.4%	-126.3%

Risk & Volatility

A beta of 2.24 shows that Novelion Therapeutics Inc. is 124.00% more volatile than Standard and Poor’s 500. Competitively, Coherus BioSciences Inc. is 263.00% more volatile than Standard and Poor’s 500, because of the 3.63 beta.

Liquidity

Novelion Therapeutics Inc. has a Current Ratio of 0.2 and a Quick Ratio of 0.2. Competitively, Coherus BioSciences Inc.’s Current Ratio is 5.3 and has 5.3 Quick Ratio. Coherus BioSciences Inc.’s better ability to pay short and long-term obligations than Novelion Therapeutics Inc.

Analyst Ratings

The Recommendations and Ratings for Novelion Therapeutics Inc. and Coherus BioSciences Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Novelion Therapeutics Inc.	0	0	0	0.00
Coherus BioSciences Inc.	0	0	2	3.00

On the other hand, Coherus BioSciences Inc.’s potential upside is 69.38% and its average target price is $25.

Insider and Institutional Ownership

The shares of both Novelion Therapeutics Inc. and Coherus BioSciences Inc. are owned by institutional investors at 48.8% and 98.8% respectively. Insiders owned 0.8% of Novelion Therapeutics Inc. shares. Insiders Competitively, owned 0.4% of Coherus BioSciences Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Novelion Therapeutics Inc.	-12.1%	22.7%	24.93%	-68.65%	-71.36%	38.1%
Coherus BioSciences Inc.	1.49%	11.66%	36.64%	-25.41%	53.37%	66.08%

For the past year Novelion Therapeutics Inc. was less bullish than Coherus BioSciences Inc.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.